News & Updates

Show Multimedia Only

Nirsevimab reduces RSV-related outcomes in infants

25 Apr 2025

Immunoprophylaxis with nirsevimab results in a 74-percent decrease in hospitalization and 85-percent reduction in paediatric intensive care unit (PICU) admissions due to respiratory syncytial virus (RSV)-related bronchiolitis, a study has shown.

Nirsevimab reduces RSV-related outcomes in infants

25 Apr 2025

MRSA infection may be detrimental to children with cystic fibrosis

25 Apr 2025

Among children with cystic fibrosis, those who contract methicillin-resistant Staphylococcus aureus (MRSA) infection appear to have worse respiratory outcomes, including increased antibiotic exposure and breathing obstruction, as reported in a retrospective study.

MRSA infection may be detrimental to children with cystic fibrosis

25 Apr 2025

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction

14 Apr 2025

Treatment with nirmatrelvir-ritonavir yields reductions in the risk of acute respiratory failure and pneumonia in COVID-19 patients with advanced kidney function, according to a retrospective matched cohort study.

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction

14 Apr 2025

More infections diagnosed after COVID-19

13 Apr 2025 by

Patients with an acute SARS-CoV-2 infection tend to have a subsequent increase in diagnosed infections over the next 12 months, according to new research.

More infections diagnosed after COVID-19

13 Apr 2025

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

New drug applications approved by US FDA as of 16-31 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

HIV-exposed, uninfected children show growth lag

08 Apr 2025

Children exposed to HIV but uninfected appear to have an initial growth deficit at birth that persists for at least the first 24 months of life, according to a meta-analysis.

HIV-exposed, uninfected children show growth lag

08 Apr 2025

World’s first liquid-bodied robot eradicates biofilms on complex surfaces

08 Apr 2025 by

An international research team led by the Chinese University of Hong Kong (CUHK) has developed the world’s first liquid-bodied robot for biofilm eradication on complex surface topographies.

World’s first liquid-bodied robot eradicates biofilms on complex surfaces

08 Apr 2025

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

03 Apr 2025 by

Preterm and very low birthweight (VLBW) infants who have been treated with ganciclovir (GCV) or oral valganciclovir (valGCV) for cytomegalovirus (CMV) disease are more likely to experience adverse events than term infants, a study has shown.

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

03 Apr 2025

Penicillin allergy delabelled in 90 percent of patients after evaluation

03 Apr 2025 by

Research from Queen Mary Hospital in Hong Kong shows that 90 percent of patients with suspected penicillin allergy were delabelled after undergoing Prospective Assessment of Penicillin Allergy (PAPA), and one in six of them received penicillins safely ≥6 months later.

Penicillin allergy delabelled in 90 percent of patients after evaluation

03 Apr 2025

Zero HIV acquisition, high persistence through 1 year with cabotegravir LA as PrEP for MSM, transgender men

03 Apr 2025 by

“Zero HIV acquisition” is a milestone that cabotegravir LA as PrEP has realized in the PILLAR real-world trial, along with high persistence observed through 12 months among 201 MSM and transgender men

Zero HIV acquisition, high persistence through 1 year with cabotegravir LA as PrEP for MSM, transgender men

03 Apr 2025

News & Updates

Filter by Specialty:

Specialty:

Nirsevimab reduces RSV-related outcomes in infants

Nirsevimab reduces RSV-related outcomes in infants

MRSA infection may be detrimental to children with cystic fibrosis

MRSA infection may be detrimental to children with cystic fibrosis

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction

Nirmatrelvir-ritonavir for COVID-19 works in patients with advanced kidney dysfunction

More infections diagnosed after COVID-19

More infections diagnosed after COVID-19

Original New Drug Application Approvals by US FDA (16-31 March 2025)

Original New Drug Application Approvals by US FDA (16-31 March 2025)

HIV-exposed, uninfected children show growth lag

HIV-exposed, uninfected children show growth lag

World’s first liquid-bodied robot eradicates biofilms on complex surfaces

World’s first liquid-bodied robot eradicates biofilms on complex surfaces

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

Ganciclovir/valganciclovir tied to adverse effects in preterm infants with CMV

Penicillin allergy delabelled in 90 percent of patients after evaluation

Penicillin allergy delabelled in 90 percent of patients after evaluation

Zero HIV acquisition, high persistence through 1 year with cabotegravir LA as PrEP for MSM, transgender men

Zero HIV acquisition, high persistence through 1 year with cabotegravir LA as PrEP for MSM, transgender men